CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLRs), today reported financial results for the second quarter ended June 30, 2010.
“We are progressing the clinical development programs of IMO-2125, our lead candidate for chronic hepatitis C virus infection, and IMO-3100, our lead candidate for autoimmune and inflammatory diseases,” said Sudhir Agrawal, D.Phil., Chief Executive Officer and Chief Scientific Officer. ”During the second half of this year, we expect data to be available from ongoing clinical trials of IMO-2125 in both null responder and treatment naïve HCV patients, and data on the safety and mechanism of action of IMO-3100 in healthy subjects. In addition, our collaborator, Merck KGaA, is advancing the clinical development of IMO-2055 in oncology.”
“Idera ended the second quarter of 2010 with $32.8 million in cash, cash equivalents, and investments. Net cash used in operations for the first six months of 2010 was $7.4 million. With the addition of approximately $14 million in net proceeds from this week’s financing, we believe that we have the financial resources to fund the planned continued clinical development of IMO-3100 and IMO-2125,” commented Lou Arcudi, Chief Financial Officer.
Second Quarter and Six-Month 2010 Results
The Company reported a net loss of $5.3 million, or $0.23 per diluted share, for the three months ended June 30, 2010, compared to a net income of $3.8 million, or $0.16 per diluted share, for the same period in 2009. For the six-month period, the Company’s net loss was $7.2 million, or $0.31 per diluted share, compared to a net income of $3.6 million, or $0.15 per diluted share, for the same period in 2009.
Total revenues for the three months ended June 30, 2010 were $4.4 million compared to $11.5 million for the same period in 2009. For the six-month period, revenues totaled $10.0 million compared to $17.8 million for the same period in 2009.
Research and development expenses for the three months ended June 30, 2010 totaled $7.0 million compared to $5.4 million for the same period in 2009. For the six-month period, R&D expenses totaled $11.5 million compared to $9.9 million for the same period in 2009.
General and administrative expenses for the three months ended June 30, 2010 totaled $2.8 million compared to $2.1 million for the same period in 2009. For the six-month period, G&A expenses totaled $5.5 million compared to $4.3 million for the same period in 2009.
As of June 30, 2010, cash, cash equivalents and investments totaled approximately $32.8 million compared to $40.2 million at December 31, 2009.
In addition, on August 5, 2010, the Company received net proceeds of approximately $14 million from a registered direct offering that was announced on August 2, 2010.
Clinical and Preclinical Programs
IMO-2125, a TLR9 Agonist, in Chronic Hepatitis C Virus (HCV) Infection
In April 2010, during the 45th Annual Meeting of the European Association for the Study of the Liver (EASL), the Company presented positive interim data from this trial through the dose level of 0.32-mg/kg/week for four weeks, comprising 33 null responder HCV patients treated with IMO-2125 and 8 null responder HCV patients who received placebo treatment. Based on the data presented at EASL, the clinical trial was extended to a fifth cohort at the dosage of 0.48 mg/kg/week for four weeks and recruitment is continuing at this dose level. We also are recruiting a cohort of eight null responder HCV patients to evaluate the safety and the effect on HCV viral load of twice-weekly IMO-2125 administration for four weeks. The clinical trial of IMO-2125 monotherapy in null responder HCV patients is being conducted at multiple sites in the U.S.
The Company expects data from the Phase 1 clinical trial of IMO-2125 monotherapy in null responder HCV patients to be available in the fourth quarter of 2010.
In this clinical trial, treatment-naïve HCV patients receive IMO-2125 by subcutaneous injection once per week for four weeks at escalating dose levels of 0.08, 0.16, and 0.32 mg/kg in combination with daily oral administration of standard doses of ribavirin. The current plans for this trial are to evaluate IMO-2125 plus ribavirin in a total of 48 patients. In addition, a total of 12 patients are planned to receive pegylated recombinant alfa-2a interferon plus ribavirin as the control arm. The primary objective of the trial is to assess the safety and tolerability of IMO-2125 in combination with standard doses of ribavirin. In addition, this trial is designed to monitor the effect of treatment on HCV viral load and on activation of the immune system. The clinical trial is currently being conducted at sites in France and Russia.
The Company expects preliminary data from the Phase 1 clinical trial of IMO-2125 in combination with ribavirin in treatment-naïve HCV patients to be available in the fourth quarter of 2010.
The Company has begun preparations for a 12-week Phase 2 clinical trial of IMO-2125 administered in combination with ribavirin to patients with chronic HCV infection towards intended initiation by the end of the year.
IMO-3100, a Dual Antagonist of TLR7 and TLR9, in Autoimmune and Inflammatory Diseases
IMO-3100 has shown activity in various preclinical models of autoimmune and inflammatory diseases, including lupus, rheumatoid arthritis, psoriasis and hyperlipidemia. As a first step in the clinical development of IMO-3100, we are conducting Phase 1 clinical trials in healthy subjects to evaluate safety and mechanism of action prior to the initiation of clinical trials in patients with autoimmune disease.
In January 2010, the Company initiated a single-dose, dose escalation, Phase 1 clinical trial of IMO-3100 in healthy subjects. In this trial, six healthy subjects in each of five dosage cohorts received single doses of IMO-3100 from 0.04 to 0.64 mg/kg. Six additional subjects each received a single dose of placebo. The primary objective was evaluation of safety and tolerability. Secondary objectives were to characterize the blood levels of IMO-3100 and to assess the pharmacodynamic mechanism of action through the response of peripheral blood mononuclear cells to agonists of TLR7 and TLR9. The trial was conducted at a single U.S. site.
In June 2010, the Company announced preliminary results from the Phase 1 single-dose, dose escalation clinical trial of IMO-3100. IMO-3100 was well tolerated at all dose levels. Peripheral blood mononuclear cells from subjects who received IMO-3100 showed suppression of immune responses mediated through TLR7 and TLR9. The immune responses monitored included induction of tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), interferon-alpha (IFN-α), and other pro-inflammatory cytokines. Peripheral blood mononuclear cells from placebo-treated subjects did not show any consistent suppression of immune responses mediated through TLR7 or TLR9.
The Company is planning to present detailed results of the Phase 1 single-dose, dose escalation clinical trial of IMO-3100 in healthy subjects at a scientific meeting in the fourth quarter of 2010.
In July 2010, the Company initiated a four-week multiple-dose clinical trial of IMO-3100 in healthy subjects. The purpose of the multiple-dose clinical trial is to evaluate the safety, blood levels of IMO-3100, and pharmacodynamic mechanism of action of IMO-3100 with multiple-dose subcutaneous administration over four weeks. The trial is designed to include 16 subjects treated with IMO-3100 and eight subjects treated with placebo.
The Company expects preliminary data from the Phase 1 multiple-dose clinical trial of IMO-3100 in healthy subjects to be available in the fourth quarter of 2010.
The Company expects that the safety and pharmacodynamic mechanism of action data from the Phase 1 clinical trials in healthy subjects will help move the clinical evaluation of IMO-3100 rapidly into selected autoimmune disease indications. The Company intends to identify an initial autoimmune disease indication for further clinical development of IMO-3100 and to initiate a Phase 2 clinical trial by the end of 2010.
EMD 1201081 (IMO-2055), a TLR9 Agonist, in Cancer Treatment (Collaboration with Merck KGaA)
In December 2007, the Company entered into an exclusive, worldwide license agreement with Merck KGaA to research, develop and commercialize products containing its TLR9 agonists for the treatment of cancer, excluding cancer vaccines. Merck KGaA currently is conducting the following clinical trials of EMD 1201081:
IMO-2134, a TLR9 Agonist, for Respiratory Diseases
During our collaboration with Novartis, IMO-2134 was identified as a lead compound for development in asthma and allergy indications and Novartis initiated a Phase 1 clinical trial of IMO-2134, also known as QAX935. Upon the termination of the research collaboration and option agreement in February 2010, the Company regained the rights to IMO-2134. The Company is currently evaluating the next steps in developing IMO-2134 for respiratory diseases.
TLR7, 8 and 9 Agonists as Vaccine Adjuvants (Collaboration with Merck & Co., Inc.)
In December 2006, the Company and Merck & Co., Inc. (now Merck Sharp & Dohme Corp. and referred to herein as Merck) entered into an exclusive license and research collaboration agreement to research, develop and commercialize vaccine products containing the Company’s TLR7, 8, and 9 agonists in the fields of oncology, infectious diseases and Alzheimer’s disease. As part of the agreement, the two companies engaged in a research collaboration to generate novel agonists targeting TLR7 and TLR8, incorporating both Merck and Idera chemistry, for use in the licensed fields. In November 2009, Merck extended the research collaboration with the Company for a fourth year to December 2010. Under the terms of the agreement, Merck is funding the research and development activities under the collaboration.
Scientists from Merck and Idera have co-authored the following presentation and publication:
TLR7 and TLR8 Agonists
The Company has created synthetic stabilized immune modulatory RNA (SIMRA) compounds that mimic viral RNA and induce immune responses by functioning as agonists of TLR7 and TLR8. The Company is continuing to study selected dual TLR7 and TLR8 agonists in preclinical models of hematological cancers and has observed antitumor activity of a dual agonist of TLR7 and TLR8 as monotherapy and in combination with selected targeted drugs currently approved for cancer treatment. The Company intends to select a dual TLR7 and TLR8 agonist as a lead drug candidate by the end of the year.
The Company is planning to present preclinical data on its dual agonist of TLR7 and TLR8 in models of hematological cancers at a scientific meeting in the fourth quarter of 2010.
The Company has identified antisense compounds targeted to human TLRs 2, 3, 4, 5, 7, 8 and 9 and to the TLR-associated signaling protein MyD88. The Company is studying these compounds for potential applications in autoimmune and inflammatory diseases.
The Company’s intellectual property portfolio contains over 500 patents and patent applications worldwide. In June 2010, the Company was again recognized by the Patent Board™ as one of the top 35 companies in the biotechnology field based on its technology and intellectual property advances. The Patent Board is an independent group that tracks and analyzes intellectual property and technology assets across 17 industries globally and publishes its results in the Wall Street Journal.
Immune Modulatory Oligonucleotide (IMO®) Technology
This portfolio holds over 290 patents and patent applications worldwide covering the Company’s IMO technologies and includes claims covering novel agonists of TLRs 7, 8, and 9, and antagonists of TLR7 and TLR9. These patents and patent applications include claims covering IMO-2055, IMO-2125, IMO-2134, and IMO-3100. The Company was granted the following U.S. patents during the second quarter:
In addition to the recently issued U.S. patents, the Company was granted: AU 20044206820, corresponding to U.S. Patent No. 7,632,822, entitled “Modulation of Immunostimulatory Properties of Oligonucleotide-Based Compounds By Using Modified Immunostimulatory Dinucleotides;” AU 2005222909, corresponding to U.S. Patent Application No. 11/078,654, entitled “Enhanced Activity of HIV Vaccine Using a Second Generation Immunomodulatory Oligonucleotide;” AU 20044304770, corresponding to U.S. Patent No. 7,713,535, entitled “Modulation of Immunostimulatory Properties by Small Oligonucleotide-Based Compounds;” and IN 240192, corresponding to U.S. Patent Application No. 10/865,245, entitled “Stabilized Immunomodulatory Oligonucleotides.”
The Company’s antisense technology portfolio includes 210 patents and patent applications worldwide owned or licensed by Idera covering novel antisense compounds and methods of their use. These patents and patent applications include claims covering second-generation antisense chemistry, oral delivery of second-generation antisense compounds, and certain genes, antisense sequences, and therapeutic targets (including various TLRs and signaling molecules).
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune and inflammatory diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances. For more information, visit www.iderapharma.com.
Idera Forward Looking Statements
This press release contains forward-looking statements concerning Idera Pharmaceuticals, Inc. that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "estimates," "intends," "should," "could," "will," "may," and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Idera's actual results to differ materially from those indicated by such forward-looking statements, including whether products based on Idera's technology will advance into or through the clinical trial process on a timely basis or at all and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if the Company's products receive approval, they will be successfully distributed and marketed; whether the Company's collaborations with Merck KGaA and an affiliate of Merck Sharp & Dohme Corp., will be successful; whether the patents and patent applications owned or licensed by the Company will protect the Company’s technology and prevent others from infringing it; whether Idera's cash resources will be sufficient to fund the Company's operations; and such other important factors as are set forth under the caption "Risk Factors" in Idera's Quarterly Report on Form 10-Q for the three months ended June 30, 2010, which important factors are incorporated herein by reference. Idera disclaims any intention or obligation to update any forward-looking statements.
Tarceva is a registered trademark of OSI Pharmaceuticals, Inc. Avastin is a registered trademark of Genentech, Inc. Erbitux is a registered trademark of ImClone LLC. The Patent Board is a trademark of The Patent Board.
Idera Pharmaceuticals, Inc.
Condensed Statements of Operations
(in thousands, except per share data)
|Three Months Ended
|Six Months Ended
|Research & Development||6,961||5,413||11,547||9,890|
|General & Administrative||2,784||2,133||5,516||4,282|
|Total Operating Expenses||9,745||7,546||17,063||14,172|
|Income (Loss) from Operations||(5,359)||3,951||(7,100)||3,628|
|Income (Loss) Before Income Taxes||(5,296)||3,982||(7,239)||3,730|
|Income Tax Provision||-||(140)||-||(140)|
|Net (Loss) Income||$||(5,296)||$||3,842||$||(7,239)||$||3,590|
Basic Net (Loss) Income per Share
|Diluted Net (Loss) Income per Share||$||(0.23)||$||0.16||$||(0.31)||$||0.15|
|Shares Used in Computing Basic Net
(Loss) Income per Share
|Shares Used in Computing Diluted
Net (Loss) Income Per Share
Idera Pharmaceuticals, Inc.
Condensed Balance Sheet Data
|(in thousands)||June 30,||December 31,|
|Cash, Cash Equivalents|
|Accounts Payable and Accrued Liabilities||$||6,063||$||2,369|
|Total Liabilities &|
KEYWORDS: United States North America Massachusetts
INDUSTRY KEYWORDS: Health Biotechnology